Sartorius Stedim Biotech (DIM) Q2 2026 earnings summary

Executive summary

• Achieved solid top-line growth and improved profitability in H1 2026, with strong cash flow generation and continued progress on financial priorities; all regions contributed positively, led by high-margin consumables and services, while equipment stabilized and returned to slight growth.

• Underlying EBITDA margin improved to 31.4%–30.3%, with underlying EBITDA up to €479 million and net profit rising 17.6% to €181 million.

• Free cash flow rose sharply, up over 70% to €208 million or nearly doubled to €199 million; deleveraging remains on track.

• Management confirmed full-year 2026 guidance and introduced new mid-term targets for sustainable growth above market levels.

• Received substantial U.S. tariff refunds, with customer compensation for surcharges impacting reported results.

Financial highlights

• Group sales revenue increased by 7.7% operationally in constant currencies (up to €1,811 million), with reported growth of 2.5%–6.4% due to tariff-related effects.

• Underlying EBITDA margin improved to 31.4%–30.3%; underlying net profit increased by 2% to €172 million, reported net profit up nearly 51% to €122 million or 17.6% to €181 million.

• Free cash flow rose by over 70% to €208 million; operating cash flow up 25%–39.4% to €364 million or €341 million.

• CapEx ratio at 8.9%–9.3%, with full-year expectation of around 12.5%.

Outlook and guidance

• Full-year group sales revenue growth expected at 5%–10% in constant currencies; underlying EBITDA margin forecast slightly above 30%–31%.

• BPS guidance: 6%–10% growth; LPS: 2%–6%, with MatTek contributing up to 2.8 percentage points.

• CapEx ratio to remain at prior year level; net debt to underlying EBITDA expected slightly above 2–3x at year-end.

• FX headwinds and tariff compensation expected to reduce reported revenue growth by about 2 percentage points or up to €35 million.

• New mid-term targets: organic sales revenue growth of 9%–12% per year and EBITDA margin expansion of 60–85 bps annually from 2027 onward.